Table 1

Patient clinical characteristics and profiles of endothelin-1, C-terminal fragment, and neutral endopeptidase 24.11

Risk factorsGroup 1A (n=30)Group 1B (n=28)Group 2A (n=24)Group 2B (n=18)
Values are mean (SD) unless otherwise indicated
*p<0.001 among 4 groups via ANOVA
**p<0.05 among 4 groups via ANOVA
†p<0.01 among 4 groups via ANOVA
‡Baseline versus 10 minutes.
Age (years)58 (12)59 (14)55 (16)56 (18)
Males18 (60%)16 (59%)15 (62%)12 (66%)
Hypertension8 (27%)6 (21%)4 (17%)3 (17%)
Diabetes mellitus3 (10%)2 (7%)2 (8%)2 (11%)
Smoking12 (40%)10 (36%)10 (42%)8 (44%)
Hyperlipidemia2 (7%)1 (4%)1 (4%)1 (6%)
Haemoglobin (g/dl)13.0 (1.8)13.1 (1.7)13.4 (1.7)13.3 (2.0)
Leucocyte (×1000)* 9.7 (2.5)9.8 (2.6)7.1 (1.8)6.9 (1.8)
Neutrophil (%)67 (11)66 (12)64 (13)64 (13)
Monocyte (%)7.4 (3.0)7.5 (2.9)7.9 (3.5)6.2 (3.4)
Platelet (×1000)272 (86)270 (84)266 (88)270 (90)
NYHA functional class
    Class I0024 (100%)18 (100%)
    Class II0000
    Class III22 (73%)20 (71%)00
    Class IV8 (27%)8 (29%)00
LVEF (echocardiography)**22 (8)22 (10)62 (10)64 (12)
LVEF (ventriculography)20 (6)21 (8)
Endothelin-1 (pmol/l)
    Baseline*3.2 (0.8)3.3 (0.8)1.7 (0.6)1.6 (0.5)
    10 min*1.9 (0.7)3.4 (0.9)1.6 (0.6)1.5 (0.6)
    Difference (95% CI)†1.3 (0.9 to 1.7)0.1 (0 to 0.5)0.1 (0 to 0.4)0.1 (0 to 0.3)
    p Value‡<0.0010.710.730.78
C-terminal peptide (pmol/l)
    Baseline*0.9 (0.3)0.9 (0.4)0.2 (0.3)0.2 (0.2)
    10 min*1.9 (0.6)0.9 (0.5)0.4 (0.4)0.3 (0.3)
    Difference (95% CI)†1.0 (0.6 to 1.4)0.1 (0 to 0.3)0.2 (0 to 0.4)0.1 (0 to 0.2)
    p Value‡<0.0010.830.650.55
NEP (nmol/mg protein)
    Baseline*5.22 (1.40)5.28 (1.50)4.76 (1.38)4.42 (1.68)
    10 min*9.44 (1.68)5.18 (1.70)8.54 (1.88)4.56 (1.92)
    Difference (95% CI)†4.21 (3.58 to 4.92)0.10 (0 to 0.90)3.78 (2.99 to 4.57)0.14 (0 to 1.04)
    p Value‡<0.0010.27<0.0010.64